The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug targets for mental health conditions.
A key priority for us whilst reviewing applications is whether proposals are supported by robust evidence linking the molecular target to human disease and of target modulation having a therapeutic effect. We are perfectly positioned to support researchers further develop or validate this initial package of evidence.
Applications which are supported by robust evidence that links the target to the human condition and provide a sound therapeutic hypothesis of how to target modulation may have a therapeutic effect stand the best chance of success.
Deadline to apply is 1st August 2022.
